Adempas (Riociguat) Patent Expiration, LOE Window & CMS Spending

Adempas (Riociguat) by Bayer: FDA Orange Book core substance LOE 2034-02-18, 1 AB generics, $802.7M 2024 CMS Part D & Medicaid spend, and 20 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBayer
FDA Application & PathwayN204819 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2034-02-18
Last Listed Patent or Exclusivity Date2034-02-18
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$802.7M
2024 Medicare Part D Spend$694.2M
2024 Medicaid Spend$108.5M
Reported Wholesale Price Change (CA SB 17)20 WAC filings (max 19.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.